Alzheimer Society of Canada position on aducanumab decision


The Alzheimer Society of Canada has been made aware of the decision by Biogen Canada Inc. to withdraw its submission of aducanumab from regulatory review by Health Canada as a treatment for people living with early stages of Alzheimer’s disease.

Alzheimer Society of Canada wordmark and identifier.

This decision will disappoint many people who had experienced positive responses to trials of the treatment, as well as those who had watched with interest and supported its approval for use in Canada.

The Alzheimer Society of Canada respects the decision made by Biogen and renews its call for additional funding for dementia research. Canada’s per capita funding commitments are far behind the funds allocated for cancer and heart disease and we rank well behind several of our G7 peers.

This must change so that new breakthroughs can be developed, tested and approved to provide hope for people living with dementia.

What should Canadians know about aducanumab? Or Aduhelm?

Aducanumab (brand name Aduhelm) is an Alzheimer's disease drug that received much global news coverage in 2021 and 2022. The drug is not available in Canada, as drug-maker Biogen withdrew it from Health Canada review in June 2022. Find more information and details here.

Learn more
Healthcare provider showing a senior woman in her care something on her tablet.

What is the process for approving dementia drugs in Canada?

Many people ask us how new dementia drugs are approved in Canada. In short, these drugs go through the same regulatory process that any other drug does. Here is more information about how drugs are approved in Canada – and which medications have made the grade for major dementias so far.

Learn more
Alzheimer Drugs Pills

The Alzheimer Society Research Program

On this page, learn more about the Alzheimer Society Research Program, including funding opportunities for researchers, when applications open and highlights from previous ASRP funded research.

Learn more
The Alzheimer Society Research Program